Eton Pharmaceuticals, Inc.ETONNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

globenewswire.com

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the licensing of U.S. marketing rights to an ultra-rare disease product candidate. Once approved, the product is expected to be the first and only generic alternative to a product used to treat an ultra-rare condition that impacts fewer than 100 patients in the United States.

seekingalpha.com

Eton Pharmaceuticals: An Undervalued Small Cap With High Growth

Eton offers a diversified, acquisition-driven portfolio in ultra-rare pediatric endocrinology and metabolic diseases, targeting significant peak sales potential. My DCF-based Fair Value is $28.1, representing 85% upside; optimistic scenarios suggest up to $40 per share, while downside risk is mitigated by product diversification. Revenue growth, free cash flow positivity, and declining SG&A margins support a Buy-to-Strong Buy stance at $15.17, despite high uncertainty from US drug pricing.

globenewswire.com

Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th

DEER PARK, Ill., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team, will host a fireside chat at the Piper Sandler 37th Annual Healthcare Conference being held in NYC as follows: DATE: Thursday, December 4, 2025 TIME: 9:30AM ETLOCATION: Lotte New York Palace To schedule a 1x1 meeting with the Company, please contact your Piper Sandler institutional sales representative.

defenseworld.net

Acadian Asset Management LLC Sells 9,713 Shares of Eton Pharmaceuticals, Inc. $ETON

Acadian Asset Management LLC decreased its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 2.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 392,715 shares of the company's stock after selling 9,713 shares during the quarter. Acadian Asset Management

globenewswire.com

Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th

DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference being held November 18, 2025 in New York, NY.

seekingalpha.com

Eton Pharmaceuticals, Inc. (ETON) Q3 2025 Earnings Call Transcript

Eton Pharmaceuticals, Inc. ( ETON ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - President, CEO & Director James Gruber - CFO, Treasurer & Secretary Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division Swayampakula Ramakanth - H.C.

zacks.com

Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates

Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.13. This compares to earnings of $0.02 per share a year ago.

globenewswire.com

Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growth Q3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP fully diluted EPS of $0.04, and Adjusted EBITDA of $2.9 million ET-600 NDA accepted for review, assigned PDUFA date of February 25, 2026 GALZIN® launch ahead of plan; exceeded previous year-end target of 200 active patients Held positive FDA meeting clarifying pathway to KHINDIVI™ label expansion Submitted proposed clinical study to support INCRELEX® label expansion Generated $12.0 million of cash from operations in the quarter Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2025.

globenewswire.com

Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025.

globenewswire.com

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA.

seekingalpha.com

Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David C. Krempa - Chief Business Officer James R.

seekingalpha.com

Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options

Eton Pharmaceuticals offers GARP potential, focusing on ultra-rare disease drugs acquired at low cost, with a lean, specialized sales force and positive cash flow. My DCF model shows 80%-87% upside to fair value ($26.17) in the base case, with even higher potential in optimistic scenarios. Risks include pipeline failures and US drug price pressures, but even pessimistic scenarios suggest current valuation is fair, limiting downside.

zacks.com

Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates

Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.12 per share a year ago.

fool.com

Eton (ETON) Q2 Revenue Jumps 108%

Eton Pharmaceuticals (ETON), a biopharmaceutical company focused on rare diseases, posted earnings for Q2 2025 on August 7, 2025. The main highlight was a strong revenue increase from both core and recently acquired products.

globenewswire.com

Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growth Q2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of $3.1 million Launched KHINDIVI™ (hydrocortisone) Oral Solution Reached 100 active INCRELEX® patients, ahead of previous guidance of year end Company projects reaching an annual revenue run rate of $80 million in Q3, one quarter ahead of previous guidance Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2025.

zacks.com

Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Eton Pharmaceuticals (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

globenewswire.com

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

seekingalpha.com

Eton Pharma Near Term Catalysts Vanish

Important near-term catalysts for ETON have been eliminated due to insider stock sales and a disappointing partial FDA approval for their new drug, Khindivi. Insider sales by the CEO and CBO after Q1 2025 earnings suggest no imminent M&A activity and have dented investor confidence. Khindivi's FDA approval excluded the key under-5 age group, removing the potential for a Khindivi driven near-term revenue guidance beat.

globenewswire.com

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

- NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the Company's New Drug Application (NDA) for ET-600, a proprietary patented formulation of desmopressin oral solution, has been accepted for review by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 25, 2026.

globenewswire.com

Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes

DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will be added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market closes on June 27, as part of the 2025 Russell Indexes reconstitution.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance